High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department

Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07278648

Enrollment

150

Registered

2025-12-12

Start date

2026-02-05

Completion date

2026-03-01

Last updated

2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Disease

Keywords

Antithrombotic Treatment, Hemorragic Event, Anticoagulants

Brief summary

This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.

Interventions

OTHERAntithrombotic therapy

Anticoagulant treatment prescribed at discharge from an acute care unit

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes: B01AA - Vitamin K antagonists: warfarin and acenocoumarol B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, … B01AE - Direct thrombin inhibitors: dabigatran B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban

Exclusion criteria

* Those who are not part of the CSAPG healthcare area. * Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.

Design outcomes

Primary

Measure	Time frame	Description
Hemorragic event	Day 90 from baseline	Proportion of patients who experience a hemorrhagic event within 90 days of hospital discharge

Countries

Spain

Contacts

Primary ContactMar Saavedra

msaavedra@csapg.cat0034938960025

Backup ContactNoemí Casaponsa

recerca@csapg.cat0034938960025

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026